Nurix Therapeutics (NASDAQ:NRIX) Shares Gap Up to $14.65

Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX) gapped up before the market opened on Wednesday . The stock had previously closed at $14.65, but opened at $15.10. Nurix Therapeutics shares last traded at $15.02, with a volume of 55,095 shares trading hands.

Analyst Ratings Changes

Several research firms have recently issued reports on NRIX. HC Wainwright reduced their target price on shares of Nurix Therapeutics from $35.00 to $19.00 and set a “buy” rating for the company in a research note on Tuesday, February 20th. Morgan Stanley upped their target price on shares of Nurix Therapeutics from $9.00 to $10.00 and gave the stock an “equal weight” rating in a research note on Monday, February 26th. Wells Fargo & Company reduced their target price on shares of Nurix Therapeutics from $23.00 to $20.00 and set an “overweight” rating for the company in a research note on Friday, February 16th. Needham & Company LLC reiterated a “buy” rating and issued a $31.00 target price on shares of Nurix Therapeutics in a research note on Tuesday, April 9th. Finally, Robert W. Baird upped their target price on shares of Nurix Therapeutics from $24.00 to $25.00 and gave the stock an “outperform” rating in a research note on Thursday, April 11th. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $21.33.

Nurix Therapeutics Stock Up 2.6 %

The stock’s fifty day moving average is $13.13 and its two-hundred day moving average is $9.44.

Nurix Therapeutics (NASDAQ:NRIX) last issued its quarterly earnings results on Thursday, February 15th. The company reported ($0.77) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.26). The company had revenue of $15.16 million during the quarter, compared to analysts’ expectations of $30.66 million. Nurix Therapeutics had a negative return on equity of 67.08% and a negative net margin of 178.93%. As a group, analysts predict that Nurix Therapeutics, Inc. will post -3.31 earnings per share for the current fiscal year.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, CFO Houte Hans Van sold 6,812 shares of the company’s stock in a transaction dated Friday, February 16th. The shares were sold at an average price of $10.02, for a total transaction of $68,256.24. Following the sale, the chief financial officer now directly owns 68,333 shares of the company’s stock, valued at $684,696.66. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Insiders have sold a total of 10,817 shares of company stock valued at $100,256 over the last three months. 7.20% of the stock is currently owned by insiders.

Institutional Investors Weigh In On Nurix Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. Credit Suisse AG lifted its holdings in Nurix Therapeutics by 7.9% during the second quarter. Credit Suisse AG now owns 15,619 shares of the company’s stock valued at $197,000 after purchasing an additional 1,145 shares during the last quarter. Barclays PLC lifted its holdings in Nurix Therapeutics by 1.9% during the fourth quarter. Barclays PLC now owns 68,739 shares of the company’s stock valued at $709,000 after purchasing an additional 1,272 shares during the last quarter. Virtus ETF Advisers LLC lifted its holdings in Nurix Therapeutics by 14.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 10,356 shares of the company’s stock valued at $107,000 after purchasing an additional 1,345 shares during the last quarter. Rhumbline Advisers lifted its holdings in shares of Nurix Therapeutics by 4.9% in the first quarter. Rhumbline Advisers now owns 33,511 shares of the company’s stock worth $469,000 after buying an additional 1,573 shares in the last quarter. Finally, Principal Financial Group Inc. lifted its holdings in shares of Nurix Therapeutics by 16.3% in the first quarter. Principal Financial Group Inc. now owns 12,804 shares of the company’s stock worth $114,000 after buying an additional 1,793 shares in the last quarter.

About Nurix Therapeutics

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.